Primary Prevention of Sudden Death in Post-Infarction Patients: When ICD Implantation is Really Cost-effective
The implantable cardioverter defibrillator (ICD) has been convincingly demonstrated to reduce mortality in randomized clinical trials that have assessed this treatment strategy for both primary and secondary prevention of sudden cardiac death [1–6]. This important advance in therapy has the potential to reduce the risk of sudden cardiac death which now affects over 400,000 persons in the United States each year. The estimated number of ICD implantations for 2003 is expected to exceed 100,000 worldwide.
KeywordsSudden Cardiac Death Implantable Cardioverter Defibrillator Implantable Cardioverter Defibrillator Therapy Implantable Cardioverter Defibrillator Implantation Secondary Prevention Trial
Unable to display preview. Download preview PDF.
- 3.Kuck KH, Cappato R, Siebels J, Ruppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Group (CASH). Circulation 102(7):748–754Google Scholar
- 4.Moss AJ, Hall J, Cannom DS et al (1996) Improved survival with an implantable cardioverter-defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 335(26):1933–1940PubMedCrossRefGoogle Scholar
- 10.ISIS-2 Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among ISIS-2 (Second international study of infarct survival). Lancet 2:349–360Google Scholar
- 12.4 S Investigators (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastain Survival Study (4S). Lancet 344:1383–1389Google Scholar
- 13.Seidl K, Senges J (2003) Worldwide utilization of implantable cardioverter-defibrilla-tor now and in the future. Cardiac Electrophysiology Review, In PressGoogle Scholar
- 14.Essebag V, Eisenberg MJ (2003) Expanding indications for defibrillators after myo-cardial infarction: risk stratification and cost effectiveness. Cardiac Electrophysiology Review (in press) Google Scholar
- 19.Domanski MJ, Sakseena S, Epstein A et al (1999) Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol 34:1090–1095PubMedCrossRefGoogle Scholar